Analysts have lowered their projections for Q4 earnings at an above-average rate in October mainly due to recent guidance cuts from COVID-era favorites Pfizer (NYSE: PFE) and Merck (NYSE: MRK), The ...
Source LinkSeekingalpha2023-11-16
Analysts have lowered their projections for Q4 earnings at an above-average rate in October mainly due to recent guidance cuts from COVID-era favorites Pfizer (NYSE: PFE) and Merck (NYSE: MRK), The ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email:uservice@ttm.financial